Axsome Therapeutics Stock (NASDAQ:AXSM), Analyst Ratings, Price Targets, Predictions

The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Mizuho on May 8, 2024. The analyst firm set a price target for $106.00 expecting AXSM to rise to within 12 months (a possible 45.21% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Mizuho, and Axsome Therapeutics maintained their buy rating.

The last upgrade for Axsome Therapeutics Inc happened on April 29, 2024 when Morgan Stanley raised their price target to $115. Morgan Stanley previously had an equal-weight for Axsome Therapeutics Inc.

The last downgrade for Axsome Therapeutics Inc happened on August 10, 2021 when Morgan Stanley changed their price target from $105 to $34 for Axsome Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $109.00 to $106.00. The current price Axsome Therapeutics (AXSM) is trading at is $73.00, which is out of the analyst’s predicted range.